The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Psoriatic Arthritis Research Continues Hunt for Biomarkers

Psoriatic Arthritis Research Continues Hunt for Biomarkers

August 17, 2018 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Denis Cristo / shutterstock.com

Denis Cristo / shutterstock.com

AMSTERDAM—Molecular signatures in synovial tissue that can be gathered through biopsies are a largely untapped resource that could help guide treatment for rheumatic conditions, an expert said at the EULAR: Annual European Congress of Rheumatology.

You Might Also Like
  • Research on Ixekizumab in Psoriatic Arthritis and More Presented at EULAR 2016
  • Bariatric Surgery Tied to Improvement in Psoriasis, Psoriatic Arthritis
  • 2013 ACR/ARHP Annual Meeting: Genetic Research Yields Clues to Pathogenesis of Rheumatoid Arthritis, Psoriatic Arthritis
Explore This Issue
August 2018
Also By This Author
  • Studies Say People with Rheumatic Disease Face Work Challenges

“I’m convinced that looking into synovial tissue provides us with tools to not only understand mechanisms of disease in rheumatoid arthritis or psoriatic arthritis, [but] it might also give us a tool to make a clinical decision,” said Bernard Lauwerys, MD, PhD, professor of rheumatology at Université Catholique de Louvain in Brussels.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In a session on emerging biomarkers in psoriatic arthritis (PsA), Dr. Lauwerys said not much data has been amassed through molecular examination of synovial tissue in the disease. But insights into rheumatoid arthritis (RA) offer encouragement for what could emerge.

For example, examinations of cell populations before and after treatment with adalimumab in RA patients have found that several subtypes decrease, particularly CD68-positive cells. This offers up a “very good marker” for treatment effect, he said.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Molecular profiling for different treatments shows some—but not all—treatments have roughly the same effect in RA patients, he said.

Rituximab, methotrexate and tocilizumab tend to have an overlapping effect, but the effect doesn’t overlap with adalimumab’s.2

“Those treatments do quite the same from a molecular point of view in synovial tissue, and this is a decrease in T cell activation,” Dr. Lauwerys said. “By contrast, there is really no common effect between adalimumab and any of those drugs. Whether a transcript is downregulated or upregulated by adalimumab doesn’t predict what will be the effect of tocilizumab.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Such information can inform clinical decision making, he said.

The Studies

In a study of PsA and other spondylo­arthritides, examination of tissue from 60 synovial biopsies found a common denominator in overexpression of a TGF-beta myogenic signature.3

In his group’s own unpublished evaluation of synovial tissue, “quite a bit of heterogeneity in molecular patterns” was found among patients with spondyloarthritides. But more work is needed to harness the power of this information, Dr. Lauwerys said. He hopes for the development of what he called a “molecular taxonomy,” groupings based on what these patterns are saying. The EULAR Synovitis Study Group is at work in this area.

“This will be interesting if we can link this to medical decisions,” he said.

Serum Biomarkers Needed

Christopher Ritchlin, MD, MPH, said the need for serum biomarkers in PsA is clear, noting the efficacy of one of the primary tools used now, C-reactive protein (CRP), is severely limited.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: Biomarkers, C-reactive protein (CRP), PsA, synovial biopsiesIssue: August 2018

You Might Also Like:
  • Research on Ixekizumab in Psoriatic Arthritis and More Presented at EULAR 2016
  • Bariatric Surgery Tied to Improvement in Psoriasis, Psoriatic Arthritis
  • 2013 ACR/ARHP Annual Meeting: Genetic Research Yields Clues to Pathogenesis of Rheumatoid Arthritis, Psoriatic Arthritis
  • Patients with Psoriasis, Psoriatic Arthritis at Increased Risk of Migraine

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.